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POST-OPERATIVE CONCURRENT CHEMORADIATION WITH MITOMYCIN-C FOR
ADVANCED HEAD AND NECK CANCER. Amar N. Rewari, Lynn D. Wilson, Yung H.
Son, John K. Joe, Douglas A. Ross, Rose J. Papac, Clarence T. Sasaki, James J. Fischer, and
Bruce G. Haffty.

Department of Therapeutic Radiology, Yale University School of

Medicine, New Haven, CT.

Purpose: Recent prospective randomized trials have shown concurrent chemo-radiation
improves local-regional control in post-operative patients with squamous cell carcinomas of
the head and neck (SCCHN) using cis-platinum based regimens. This report pools data from
three randomized trials performed at Yale that employed mitomycin-C (MC), selecting those
patients treated postoperatively, to evaluate the long term benefit of MC in the postoperative
setting and to compare these results with other recently published randomized trials.

Methods and Materials: Between 1980 and 1999, a total of 331 SCCHN patients from the
three prospective trials were enrolled. Of those patients, 205 were post-operative of which
103 were randomized to receive mitomycin-C and radiation, while 102 received radiation
alone or radiation with porfiromycin in the third trial. Patients were treated with daily
radiotherapy to a total median dose of 60 Gy over 47 days. Patients who were randomized to
MC received 15 milligrams per square meter (mg/M2) of mitomycin-C on days 5 and 47 (or
last day).

Results: The 5-year rate of local-regional control was higher in the MC arms (85.3% vs.
69.9%, p = .008). There was no statistically significant difference in overall survival or

distant metastasis. Patients had a lower percentage of high risk factors in both arms of the
study, compared to patients of the large prospective trials, including positive margins, 2 or
more positive lymph nodes, or oropharynx primary. The gains in local-regional control
realized with MC were similar to the improvements in the recently published randomized
trials using cis-platinum.

Conclusions:

These results confirm significant gains in local-regional control using

concurrent chemo-radiotherapy in the postoperative setting for patients with SCCHN. The
lack of consensus over a benefit in overall survival and distant metastasis emphasizes the
need for further prospective trials in the postoperative management of SCCHN.
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INTRODUCTION

Head and neck cancers account for nearly 4% of all newly diagnosed cancers every
year. (1) In 2000, the estimated number of new cases worldwide was 550,000. (1) At least
40% of patients presenting with squamous cell carcinomas of the head and neck have locally
advanced disease, and the associated prognosis remains disappointing. In the USA, the 5year relative survival rates for the period 1989-1995 did not exceed 45%.

Historical Data in Support of Post-Operative Radiation
Advanced squamous cell carcinomas of the head and neck (SCCHN) have markedly
poor outcomes despite decades of effort developing and evaluating various strategies aimed
at reducing recurrence and improving survival. Surgical resection followed by postoperative
radiation therapy, or radiation therapy alone were the principle modalities employed for
patients with advanced head and neck cancer for decades. In 1957, Macomb suggested that
the combination of radiation and surgery may be more efficacious than utilizing one initial
treatment and reserving the other for salvage therapy. (2)

In general, by the 1970’s

postoperative radiation therapy consisted of 60 Gray (Gy) in 30 fractions and was delivered
for the following indications: “surgical resection incomplete, cancer cells close to the margin,
surgical margins not clear, nodes positive at multiple levels, cancer through the nodal capsule
or midline primary lesion.” (3)

Despite the prevalence of adjuvant postoperative

radiotherapy, no large prospective randomized trials have ever been conducted to compare
the treatment to surgery alone for ethical reasons.

2
Several modern retrospective reviews have been performed that show a benefit to
postoperative radiation for SCCHN. Two of the largest of these studies are a Medical
College of Virginia review and a Mayo Clinic review. The Medical College of Virginia
study reviewed 444 surgical patients from the years 1982 to 1988. (4) The cohort of patients
examined was limited to those with advanced disease by selecting for 125 patients who had
extra capsular nodal extension (ECE) and/or positive resection margins (PRM). Of these 125
patients, 71 were treated with surgery alone and 54 received surgery and radiation therapy
consisting of greater than 50 Gy. Selection of treatment appeared to be more related to
physician preference than to the extent of the disease. Patients in both groups were well
balanced with respect to T and N stage. In addition, the two groups were comparable with
respect to site of primary disease and frequency of ECE/PRM. The three year disease-free
survival for the combined treatment group was 45% compared to 25% for the patients who
received surgery alone (p=.0001). (4) Local control was assessed with respect to prognostic
groups. For patients with ECE the 3 year local control rate was 66% for combined treatment
and 31% for surgery alone (p=.03). (4) For patients with PRM, the 3 year local control rate
was 49% for the combined treatment and 41% for surgery alone (p=.04). (4) For patients
with ECE and PRM, the 3 year local control was 68% for the combined group and 0% for
surgery alone (p=.0003). (3) Overall survival was improved for the patients who received
post-operative radiotherapy versus those who were observed (3 year survival 72% for
combined treatment versus 41% for surgery alone (p=.0003). (4)
In order to account for any potential imbalances in the prognostic factors between the
patients who received various treatments the Mayo Clinic group utilized a matched pair
analysis based upon known prognostic factors. (5) The matched pair analysis was performed
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to pair like patients who received surgery alone versus those who received surgery and
postoperative radiotherapy. The database for this matched pair-analysis consisted of 66
consecutive patients with N1 or N2 disease who underwent surgical resection and
postoperative radiotherapy between the years of 1974 and 1990. The data base for patients
who received surgery alone consisted of a previously published series of 265 patients with
N1 or N2 disease. (5) The patients underwent a computer generated matched pair analysis
with 56 pairs being found. Patients were matched with respect to age, gender, pathological
neck stage, number of metastatically involved nodes (≥ 4), and desmoplastic lymph node
pattern.
Of the 56 patients who received postoperative radiotherapy, the median interval
between operation and postoperative radiotherapy was 41 days, the median radiation dose
was 56 Gy. The median number of fractions was 30, and the median dose per fraction was
1.8Gy. A majority of these patients had oral cavity and oropharynx lesions (fewer larynx and
hypopharynx). The site distribution was well balanced between the treatment groups of
surgery alone versus the surgery and postoperative radiotherapy. The Mayo Clinic study
demonstrated a statistically significant improvement in survival for the group of patients who
received surgery and postoperative radiotherapy compared to surgery alone with respect to
death from cancer (2 year overall survival 60% versus 39.4%, p=0.0182). (5) Therefore, this
matched pair analysis, combined with the results from the Medical College of Virginia,
provide support to the use of postoperative radiation for the patients with advanced head and
neck malignancies.
During the past few decades there has been considerable debate over whether
preoperative radiotherapy might be better than postoperative radiation. A Radiation Therapy
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Oncology Group (RTOG) trial was conducted to further examine this question. The RTOG
73-03 trial enrolled 320 patients with Stage III and IV disease of the supraglottic larynx,
hypopharynx, oral cavity, and oropharynx and stratified them by gender, T stage, and N
stage. (6) Of the total patients, 277 were randomized to preoperative radiotherapy consisting
of 50 Gy followed by surgery versus surgical resection followed by postoperative
radiotherapy consisting of 60 Gy. The planned therapy was completed for 194 of these
patients and the disease site and stage breakdown for the two arms was well-balanced. The
overall local-regional control at four years was 48% for the patients who received
preoperative irradiation versus 65% for the patients who received postoperative radiation
(p=.04). (6) There was a trend toward an overall survival benefit for patients who received
60 Gy postoperative radiation compared to 50 Gy preoperative radiation (p=.10). (6)
Even though postoperative radiation may be better than preoperative radiation or
surgery alone, the survival rates still remain low. The poor prognosis of patients with locally
advanced HNSCC actually results from two factors. First, local and regional recurrence
remains the major obstacle to cure of locally advanced HNSCC. Second, the impact of localregional failure (LRF) on the treatment outcome is not restricted to progression or recurrence
above the clavicles only. Indeed, an analysis of more than 2,500 patients in the Radiation
Therapy Oncology Group (RTOG) database who had HNSCC showed a statistically
significant increase in the risk of distant metastasis (21% versus 38%) for patients whose
local-regional disease was not controlled, as compared with those whose disease was
controlled. (7)

Historical Data in Support of Chemo-radiation
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Chemotherapy has been added to treatment regimens since the 1970s as a way to
improve outcomes. On a biological basis, chemotherapy with cytotoxic drugs has been
shown to enhance the response of radiation. The most widely investigated drugs were a
combination of platinum derivatives and 5-fluorouracil (5-FU). These drugs act to inhibit
repair of lethal and sublethal damage induced by radiotherapy, radiosensitize hypoxic cells,
reduce tumor burden, synchronize and redistribute tumor cells into the more sensitive G2-M
cell cycle phase, and induce apoptosis. (8) It was because of these in vitro effects that
chemotherapy was tested in the clinical setting as chemotherapy alone, induction
chemotherapy, adjuvant chemotherapy following surgery and/or radiotherapy, and concurrent
chemotherapy with radiation.

The efficacy of these chemotherapy regimens has been

assessed in various meta-analyses with most showing a small benefit in terms of localregional control. (9-12)
The landmark Intergroup 0034 phase III trial validated the use of sequential
chemotherapy and radiation as an effective form of treatment with reduced toxicity. (14,15)
All patients in this study had completed surgical resection followed by randomization to
radiation alone or chemotherapy followed by radiation. The chemotherapy group received
cisplatin and 5-FU every 3 weeks after the completion of surgery. Radiation therapy in both
arms consisted of 50-60 Gy using 1.8 to 2Gy fractions per day. Low risk patients were
treated to 50-54 Gy and high risk patients were treated to 60 Gy. High risk patients were
defined as those with margins less than 5mm, extracapsular extension (ECE), or carcinomain-situ at the margins. There was no difference in local control, disease free survival, or
overall survival, but there were more distant metastases in the radiation therapy arm alone.
At 4 years there were 30% distant metastases in the radiation arm versus 20% in the
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sequential chemoradiation arm (p=.02). (14,15) Although there was no overall improvement
in local control, sub-group analysis of high risk patients showed a trend toward
improvements in local control. (14,15) Patients with high-risk factors have thus been seen as
a potential target population for concurrent chemo-radiation, which can be more toxic than
sequential therapy.

Identifying High Risk Factors
High risk factors are important prognostic indicators of who is more likely to have
local-regional failure and distant metastasis and can alter treatment regimens.

It is

particularly important to understand high risk patient populations before examining Level 1
evidence in support of concurrent chemo-radiation. RTOG 8503, which tested the value of
postoperative chemotherapy and radiation therapy, suggested three risk groupings. (14) Low
risk was defined as patients with fewer than two positive nodes, no ECE, and negative
surgical margins. Medium risk patients had at least two positive nodes or ECE, but no
positive surgical margins. High risk patients had surgical margins that were positive.
Risk assessment by clusters was developed at MD Anderson in the 1990s. Their
analysis was designed to clarify which patients needed postoperative radiotherapy, and three
main principles emerged. First, the presence of ECE of tumor beyond the capsule of a node
in the surgical specimen was an independent variable linked to a significantly increased risk
of recurrence. (16) Second, increasing combinations of two or more risk factors (i.e., oral
cavity primary, close or positive mucosal margins, nerve invasion, two or more positive
lymph nodes, largest node >3 centimeters in diameter, treatment delay >6 weeks, and Zubrod
performance status ≥2) were associated with a progressively higher risk of local failure. (16)
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Third, a follow-up study by Ang concluded that patients who had no adverse surgical
pathologic features or were low-risk did not need postoperative radiotherapy. (17) The 5year actuarial local-regional control and survival rates achieved with surgery alone in this
group were 90% and 83%, respectively. (17)

Post-Operative Concurrent Chemo-Radiation
Having identified head and neck patients with high-risk factors that could benefit
from a more aggressive approach of chemo-radiation, a number of smaller trials have been
conducted since the 1990s to examine the role of concurrent chemo-radiotherapy in this
setting.

Bachaud enrolled 83 high risk patients with stage III or IV disease and ECE and

randomized them to receive either post-operative radiation or post-operative radiation with
weekly Cisplatin chemotherapy at 50 mg/m2 for 7-9 cycles. (18, 19) Despite the small
number of patients enrolled, there were statistically significant improvements in local
regional control and overall survival (see discussion section). (18, 19) The toxicity was
tolerable although more severe than with radiation therapy alone. There was an increase in
severe acute toxicity from 18% to 41% with addition of chemotherapy and this primarily
consisted of mucositis, weight loss, nausea, and vomiting. (18, 19)
In another prospective trial of 114 patients with advanced squamous cell carcinoma of
the head and neck by Smid, mitomycin C and bleomycin were used as the chemotherapeutic
agents. Mitomycin-C is a hypoxic cell cytotoxin that has been shown to be synergistically
effective with radiation in controlling disease. (20-22)

Bleomycin is an antineoplastic

antibiotic. This trial showed statistically significant improvements in local regional control
and overall survival in the group that received the concurrent chemo-radiation (see discussion
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section). (23) Together, these two studies provided suggestive, but not conclusive, evidence
that adjuvant concurrent chemo-radiation was more efficacious than post-operative radiation
therapy alone.
To assess these results further, two large phase III multi-center trials were conducted
by the RTOG and European Oncology Radiation Therapy Commission (EORTC) to evaluate
the role of high dose concomitant chemo-radiation (chemotherapy given every 3 weeks) in
the post-operative setting. The EORTC trial #22931 enrolled 334 patients from 1994-2000
with specific criteria for inclusion related to high risk factors: stage III or IV disease, oral and
oropharynx primary with lymph nodes at levels IV or V, vascular embolisms, perineural
disease, ECE, or positive margins. The primary endpoints of the study were disease free
survival, local regional control, and overall survival. Patients were randomized to receive
either post-operative radiation to 66 Gy in 33 fractions over 6.5 weeks or chemo-radiation
using the same radiation schedule combined with three courses of cisplatin 100 mg/m2 on
days 1, 22, and 43. After 5 years, patients had a statistically significant improvement on all
endpoints. Local regional control improved from 69% to 82% with concurrent therapy
(p=.007), disease free survival improved from 36% to 47% (p=.04), and overall survival
increased from 40% to 53% (p=.02). (24) Objective acute mucositis and late toxicity were
not significantly increased in patients who received concurrent therapy. (24)
The RTOG 95-01 study similarly compared concurrent chemo-radiation with
cisplatin to post-operative radiation therapy alone. This trial consisted of 459 patients from
1995-2000 and included those individuals with high risk factors of two or more positive
lymph nodes, positive surgical margins, or ECE. The end-points were similar to the EORTC
study (i.e., disease free survival, local regional control, and overall survival.) The patients
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were randomized to receive either post-operative radiation to 60 Gy in 30 fractions over 6 Gy
fractions with or without a 0.6 Gy boost over 3 days or chemo-radiation using the same
radiation therapy schedule combined with three courses of cisplatin 100mg/m2 on days 1, 22,
and 43.

At 3 years the arm receiving concurrent chemo-radiation showed significant

improvements with respect to local regional control (82% versus 72%, p=.01) and disease
free survival (54% versus 45%, p=.04). (25) Overall survival, however, did not show
statistically significant improvement with the addition of chemotherapy (64% versus 57%,
p=.19). (25) With regard to toxicity, the addition of chemotherapy resulted in a substantially
greater incidence of severe acute side effects in this trial. Grade 3 or higher toxicity was
observed in 34% of patients treated by radiotherapy alone, but more than doubled to 77% in
the patients treated with concurrent therapy. (25) Severe late toxicity was not significantly
different between the treatments.
There is no clear explanation for the difference between overall-survival outcomes
between the RTOG and EORTC trials, although differing patient eligibility criteria and risk
stratification most likely were the main contributors. The eligibility criteria common to both
trials were ECE and positive margins. In addition, RTOG included patients with two or more
positive lymph nodes, while EORTC included patients with stage III/IV disease, enlarged
lymph nodes at level IV/V, oropharynx or oral cavity primary, vascular embolisms, and
perineural invasion. The distribution of these criteria across the two studies leads to some
interesting observations. First, 94% of the cases in the RTOG trial had N2 or N3 disease as
compared with only 57% in the EORTC trial. Second, there were a greater number of
patients with oropharynx primary, a poor prognostic indicator (see “Identifying Risk Factors”
section above), in the RTOG group than in the EORTC study. Finally, there was a greater
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proportion of patients with positive margins in the chemo-radiation arm than in the radiation
arm of the RTOG trial (27% versus 19%), while the EORTC trial showed the reverse with
more patients with positive margins in the radiation arm than the chemo-radiation arm (34%
versus 31%). In contrast, the dose levels delivered in each trial were similar (i.e., analyses of
compliance indicate that most cases received at least 60 Gy in either trial.) (8) Thus,
differences in outcomes most likely represented differences in the risk factors of the patient
populations in the two trials and will be examined in further detail in the discussion section.

Yale Data
Our institution conducted three separate prospective clinical trials from 1980 to 1999 testing
concurrent chemo-radiation with mitomycin-C in patients with head and neck cancers. (2629) As mentioned earlier, mitomycin-C is a hypoxic cell cytotoxin that has been shown to be
synergistically effective with radiation in controlling disease. All three trials did not limit
inclusion to patients receiving postoperative radiation, but also included patients who were
being treated with primary radiation. The first trial randomized patients to radiation alone or
radiation with mitomycin-C and showed improvements in local-regional control for those
who received the combined modality treatment. (28) The second trial randomized patients to
radiation alone or radiation with mitomycin-C and dicumarol. (26) Dicumarol was added
because laboratory studies suggested it enhanced the hypoxic cytotoxicity of mitomycin. (2931) In the clinical setting, however, the trial did not show any added benefit for dicumarol
beyond those already documented with the combined therapy of radiation and mitomycin-C.
(27) The third trial had drug treatment in both arms and randomized patients to either
radiation with mitomycin-C or radiation with porfiromycin. (26)

Porfiromycin is a
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methylated derivative of mitomycin-C and was shown in laboratory studies to have even
greater differential hypoxic cell cytotoxicity than mitomycin-C. (32-37)

In the clinical

setting, however, porfiromycin did not significantly improve local-regional control and only
added to increased toxicity.
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STATEMENT OF PURPOSE

The EORTC and RTOG 95-01 recently published phase III trials in the New England
Journal of Medicine that evaluated the role of concurrent chemo-radiation with cisplatin and
5-flourouracil for patients with advanced squamous cell carcinoma of the head and neck in
the post-operative setting. Both trials showed an improvement in local-regional control for
patients who received concurrent chemo-radiation, however, they differed in their survival
outcomes. While the EORTC did show a statistically significant improvement in overall
survival, the RTOG study did not. It was speculated that this difference was due to eligibility
criteria and risk stratification of the patients in the two trials.
Yale has large data sets from three separate randomized trials that used mitomycin-C
as a chemotherapeutic agent for patients receiving concurrent chemo-radiation for advanced
head and neck cancer. All three trials included patients treated in both the postoperative
setting as well as with primary radiation. However, management strategy (i.e. primary
radiotherapy versus postoperative) was a major stratifying variable, allowing separate
analysis of postoperative patients. Given the differing outcomes from the EORTC and
RTOG trials, there is a unique opportunity to use the Yale data to shed further light on the
role of post-operative concurrent chemo-radiation.
This thesis pools data from the mitomycin-C trials, limiting the analysis to those
squamous cell carcinoma of the head and neck patients who received therapy
postoperatively, and examines the role of chemo-radiation (mitomycin-C) with respect to
overall survival and local-regional control. In addition, I documented high-risk factors such
as positive margins, multiple positive lymph nodes, and oral cavity/oropharynx primary to
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compare eligibility criteria and risk stratification with the recent RTOG, EORTC and other
postoperative trials. I also conducted a sub-set analysis of these high-risk factors to see if
any was an independent prognosticator for local regional failure, distant metastases, or
reductions in overall survival.
My hypothesis is that we will see improvements in local-regional control in the postoperative patients who are treated with concurrent chemo-radiation, since we saw similar
results for all patients who were treated with this treatment in the three separate trials. I do
not anticipate seeing a survival benefit, since this was not observed in the trials. I anticipate
the two arms of our study to be well-balanced with respect to high-risk factors since our
patients were risk-stratified in the individual trials. However, I do not know how our patient
population will compare to the EORTC and RTOG, nor do I know if any of our risk factors
will be seen as an independent prognosticator for local-regional failure, distant metastases, or
reductions in survival.
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METHODS AND MATERIALS

Patient Selection
All three clinical trials were conducted at Yale University following patient
presentations at multidisciplinary head and neck tumor board conferences. The trials were
conducted by faculty members from the department of Therapeutic Radiology, and sections
of Medical Oncology, and Otolaryngology. Patients were all clinically staged and classified
according to the American Joint Commission/Tumor Node Metastasis system at the times of
their enrollment in the trials and I have restaged them according to 2002 guidelines. (38)
Eligible patients had histologically proven squamous cell carcinoma within one of the
following anatomic locations: oral cavity, oropharynx, larynx, hypopharynx, paranasal sinus,
or unknown primary. For the most part, patients had Stage III or IV carcinoma, however
patients with Stage I and II were also considered if they were deemed to be high-risk by the
tumor board which based decisions on unfavorable pathological findings, level of node
involvement, and site of primary. Patients in the postoperative as well as primary radiation
groups were eligible for the trials, but were stratified by management strategy (primary RT,
postoperative high risk, postoperative low risk). In the current analysis I included only those
patients who received radiotherapy in the postoperative setting.

Patient selection criteria

included: age between 20-80 years, no distant metastases, no prior radiation, no history of
malignancy within five years, no history of chemotherapy within three years, and no history
of peptic ulcer, esophageal varices, or bleeding disorders. Patients had to be able to tolerate
chemotherapy by having the following tests within specified Karnofsky limits: hematocrit,
white cell count, platelet count, prothrombin/partial thromboplastin time, total bilirubin,
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blood urea nitrogen level, creatinine level, calcium, phosphate, AST, and ALT. All three
prospective trials were approved by the Yale University institutional review board and all
patients gave written informed consent.
Those who met the eligibility criteria were then randomized by a biased coin method
in which balance between the treatment groups was forced with respect to primary site and
extent of disease. Patients were randomized at the time of consultation with the radiation
oncologist. Patients in trial 1, conducted from 1980 to 1986, were randomized to either
radiation alone or radiation with mitomycin-C. Patients in trial 2, conducted from 1986 to
1992, were randomized to radiation alone versus radiation with mitomycin-C and dicumarol.
Patients in trial 3, conducted from 1992 and 1999, were randomized to either mitomycin-C or
porfiromycin.

Treatment
Radiation therapy was planned by the radiation oncologists and physicists and
administered by the therapists using 4-6 MeV linear accelerators with standard fractionation
schedules of 1.8 to 2.0 Gy per day, 5 days a week. Radiation was administered using
standard bilateral or three field arrangements to encompass the primary site and regional
lymph nodes. The total dose of radiation was at the discretion of the radiation oncologist.
Patients treated postoperatively were required to receive a minimum dose of 54 Gy, but
generally received 60 Gy or more in the later years of the trials, receiving a median dose of
60 Gy over a 47 day period. There was no difference between the drug-treatment arms and
the no-drug arms with respect to total dose and duration.
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Patients randomized to receive mitomycin-C received the drug intravenously at a
dose of 15 milligrams per square meter (mg/M2) on the fifth day of the radiation course by
their medical oncologist. Patients scheduled to receive 60 Gy or more received a second
dose of mitomycin on day 47 or day 50. The second dose of mitomycin was reduced or
eliminated if grade 3 or 4 hematologic toxicity occurred. In the second trial, patients who
received mitomycin-C also received 300 mg of dicumarol on the day before mitomycin-C
and 200 mg on the day after mitomycin. In the third trial, patients who were not in the
mitomycin-C arm received a dose of porfiromycin at 40 mg/M2 intravenously on day 5 and a
second dose on day 47.

Follow-up
Patients were evaluated weekly by the radiation oncologist during the radiation
course. After the radiotherapy was complete, patients were evaluated on 1-3 month intervals
for the first 2 to 3 years, and on 6 to 12 month intervals thereafter. Tumor response, adverse
effects, and patient status were recorded by the radiation oncologist.

Data Collection and Analysis
I reviewed the charts of all the patients enrolled in the three trials and documented a
number of characteristics including: primary site of tumor, stage, radiation dose given, type
of neck dissection (e.g., radical, modified, none, ipislateral, bilateral, etc.), number of lymph
nodes sampled, number of lymph nodes with pathologic presence of disease, extra-capsular
extension, pathologic findings of surgical resection margins, type of primary surgery,
evidence of recurrence, and location of recurrence.
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Patients with biopsy or clinically diagnosed recurrences at the primary site and/or the
regional lymph nodes were labeled as local-regional relapses. Patients with clinical or
radiological evidence of metastatic disease were labeled as distant relapses. Local-regional
recurrence free survival (local-regional control) was recorded as the time from randomization
to the time of a local-regional relapse. Overall survival was recorded as the time from
randomization to the time of death.
Comparison of variable and control groups was analyzed for statistical significance
with the chi square test for all categorical variables, and the t-test for all continuous variables.
Overall survival and local-regional recurrence free survival were calculated using the
Kaplan-Meier method. (39) 1 Statistical comparisons between the treatment arms were made
using the log-rank test. (40) 2 These statistical tests were performed jointly by me and my
faculty mentor. In addition, a subset analysis of all high risk factors and their impact on
local-regional control, distant metastases, and overall survival were conducted.
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RESULTS

Patients
One hundred twenty patients were enrolled in the first trial from 1980 to 1986, 83
patients were enrolled in the second trial from 1986 to 1992, and 128 patients were enrolled
in the third trial from 1992 to 1999. Of the 331 total patients enrolled in the three trials only
316 were available for analysis. Of these 316 patients, 205 were treated postoperatively and
are the subject of this analysis. Previously published data show no effect of dicumarol. (27)
We have therefore included patients treated with mitomycin-C and dicumarol in the arm with
those just treated with mitomycin-C.

Previously published reports show no benefit to

porfiromycin. (26) We have therefore included the patients in the third trial who received
porfiromycin in the control arm. Thus of the 205 post-operative patients, 102 patients were
randomized to the Mitomycin-C/radiotherapy group and 103 were randomized to the control
arm. Retrospective record reviews were performed on these sub-groups, recording high risk
factors such as margin status and number of positive lymph nodes.

Table 1 lists the

characteristics of these patients. The table shows that both arms of our study were wellbalanced with respect to all patient variables.
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Table 1. Characteristics of Patients and Tumors
Characteristic

Sex -- no. (%)
Male
Female
Race -- no. (%)
White
Black
Asian
Other
Age -- no. (%)
< 60
> 60
Primary Site -- no. (%)
Oral Cavity
Oropharynx
Hypopharynx
Larynx
Nasopharynx
Paranasal Sinus
Unknown Primary
Tumor Stage -- no. (%)
0
1
2
3
4
Nodal Stage -- no. (%)
0
1
2
3
AJC Stage -- no. (%)
I
II
III
IV
Resection Margins -- no. (%)
Negative
Positive
Unknown
Lymph Node Status -- no. (%)
0-1 Positive
>1 Positive
Unknown

Radiotherapy
N = 103

Combined Therapy
N = 102

Total
N = 205

82 (80)
21 (20)

21 (85)
15 (15)

103
102

72 (78)
16 (17)
1 (1)
3 (3)

82 (92)
7 (8)
0 (0)
0 (0)

154
23
1
3

77 (75)
26 (25)

82 (80)
20 (20)

159
46

34 (33)
23 (22)
15 (15)
18 (17)
1 (1)
11 (11)
1 (1)

31 (31)
25 (25)
16 (15)
23 (23)
0 (0)
5 (5)
1 (1)

65
48
31
41
1
16
2

2 (2)
11 (12)
25 (27)
37 (40)
17 (19)

0 (0)
10 (11)
34 (36)
24 (25)
27 (28)

2
21
59
61
44

41 (43)
18 (19)
32 (33)
5 (5)

43 (45)
23 (24)
24 (25)
6 (6)

84
41
56
11

6 (7)
14 (15)
30 (33)
42 (46)

3 (3)
13 (14)
31 (33)
47 (49)

9
27
61
89

60 (58)
25 (24)
18 (17)

53 (53)
30 (30)
17 (17)

113
55
35

55 (54)
32 (32)
14 (14)

41 (44)
38 (40)
15 (16)

96
70
29
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Toxicity
As anticipated, the major toxicities in the mitomycin-C group were hematological,
consisting of leukopenia and thrombocytopenia. There were more mild, moderate, and
severe hematologic toxicities in the patients treated with mitomycin-C. No hematologically
related treatment deaths occurred in any trial.

Non-hematological toxicities included

mucositis and epidermitis and were not significantly different between the mitomycin-C and
the control arms. The hematological and non-hematological toxicities are outlined in Tables
2 and 3.

Table 2. Hematologic Toxicity
Radiotherapy Combined Therapy
Hemoglobin
Normal (>11)
Mild (9.5-11)
Moderate (8-9.5)
Leukopenia
Normal (>4000)
Mild (3000-4000)
Moderate (2000-3000)
Severe (1000-2000)
Life-threatening (<1000)
Thrombocytopenia
Normal (>100,000)
Mild (75,000-100,000)
Moderate (50,000-75,000)
Severe (25,000-50,000)
Life-threatening (<25,000)

Total

93
7
3

89
10
3

182
17
6

69
19
10
4
1

34
30
24
13
1

103
49
34
17
2

90
7
4
1
1

66
13
15
6
2

156
20
19
7
3
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Table 3. Non-hematologic Toxicity
Radiotherapy Combined Therapy
Mucositis
Normal
Mild
Moderate
Severe
Not Recorded
Epidermitis
Normal
Mild
Moderate
Severe
Not Recorded
Nausea/Vomiting
Normal
Mild
Moderate
Not Recorded

Total

16
20
47
17
3

17
28
28
25
4

33
48
75
42
7

43
27
19
11
3

31
30
28
11
2

74
57
47
22
5

97
0
3
3

92
6
3
1

189
6
6
4

Outcome
The 5-year rate of local-regional control for patients in the radiotherapy group was
69.9% with 31 of 103 patients failing. The 5-year rate of local-regional control was 85.3% in
the mitomycin-C group, with 15 of 102 patients failing. (p=0.008). Figure 1 summarizes
local-regional control rates in both arms at 10 years (p=0.017; mantel & haenszel chi square
= 5.69).
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Figure 1. Rates of Local-Regional Control
Patients assigned to receive concurrent chemotherapy and radiotherapy had a
higher rate of local-regional control than patients assigned to receive radiotherapy
alone. (p = .017, mantel & haenszel chi square = 5.69)

Distant recurrence rates and overall survival rates were not within 95% confidence for
statistical significance. The 5-year rate of distant metastasis was 22.3% in the radiotherapy
group and 19.0% in the mitomycin-C group (p=0.558). The 5-year overall survival rate for
patients in the radiotherapy group was 51.0% and 49.4% in the mitomycin-C group (p>0.50).
Figure 2 summarizes overall survival rates for the two arms (p>0.50). Seventy six patients in
the radiotherapy group and 81 patients in the mitomycin-C group died within 5 years from
any cause out of 205 patients treated with radiation postoperatively
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Figure 2. Rates of Overall Survival
Overall Survival did not differ significantly between groups.
(p > 0.50, mantel & haenszel chi square = 0.289)

A subset analysis was performed evaluating local-regional control for those patients
who had high-risk factors of two or more positive lymph nodes or positive margins. Node
positive patients that were randomized to receive mitomycin-C had a local-regional control
rate of 83.2% at 5 years compared to 64.4% in the control group (p=.096). Although this is
not statistically significant with 95% confidence, it is within 90% confidence and shows a
trend toward a potential benefit. The sampling of patients with positive margins was also not
statistically significant. Local-regional control was seen in 82.0% of mitomycin-C treated
patients and 70.1% of control patients at 5 years (p>0.50).

The initial trials were

underpowered to perform a subset analysis of high-risk factor patients.
Our rate of local-regional control for all post-operative patients compares similarly
with the results from the EORTC trial and the RTOG (95-01) trial which both showed a
statistically significant benefit. (24,25) The EORTC rate of local-regional relapse at 5 years
was 31% with radiotherapy and 18% with combined radiotherapy and platinum (p=.007).
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The RTOG (95-01) rate of local-regional relapse at 45 months was 30% with radiotherapy
and 19% with combined radiotherapy and platinum (p=.01). The RTOG (95-01) trial did not
show any significant benefits in terms overall survival or distant metastasis. The EORTC trial
did show a 5 year overall survival benefit with 53% in the combined therapy group and 40%
in the radiotherapy group (p=.02). Other randomized trials of patients treated with concurrent
chemo-radiotherapy showed similar gains in local-regional control. The trial by Bauchaud et
al, employing cis-platinum demonstrated a 15% improvement in local-regional control, and
the trial by Smid et al, employing Mitomycin and Bleomycin demonstrated a 17%
improvement in local-regional control. (18-19,23) The comparisons between our outcomes
and those of other concurrent chemo-radiation trials are summarized in Table 4.

Table 4. Comparable Analysis of Outcomes
n
Bauchaud et al.
RT
RT+cis-Platinum
Smid et al
RT
RT+MC+Bleomycin
EORTC
RT
RT+cis-Platinum
RTOG 95-01
RT
RT+cis-Platinum
Yale Mitomycin Trial
RT
RT+MC

LRC (%)

83

p

Overall Survival (%)

0.05
55
70

114

<0.01
13
30

0.037
69
86

334

0.036
64
74

0.007
69
82

416

0.04
40
53

0.01
72
82

205

0.19
41
49

0.008
70
85

p

>0.05
51
49

The Bauchaud, Smid, and EORTC trials all showed improvements in LRC and overall
survival, while our study mirrors RTOG (95-01) in only showing significant benefits in LRC.
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High risk factors, including positive margins, oropharynx primary, and two or greater
positive lymph nodes from our trial compared to those factors from the EORTC and RTOG
(95-01) trials are summarized in Table 5. The patient population of our trial was most
similar to the EORTC trial, except we even had fewer numbers of positive margins,
oropharynx primary, and two or more positive lymph nodes than their study.

Table 5. Patient Stratification by High-Risk Factors
Radiotherapy (%)

Combined Therapy (%)

RTOG Trial
Oropharynx
Positive Margins
2 or more LN

37
29
81

48
17
83

EORTC Trial
Oropharynx
Positive Margins
2 or more LN

28
26
56

32
31
53

Yale Mitomycin Trial
Oropharynx
Positive Margins
2 or more LN

22
24
32

25
30
40
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DISCUSSION

Advanced squamous cell carcinomas of the head and neck have markedly poor
outcomes despite decades of effort developing and evaluating various strategies aimed at
reducing recurrence and improving survival. Surgical resection followed by postoperative
radiation therapy, or radiation therapy alone were the principle modalities employed for
patients with advanced head and neck cancer for decades. Post-operative radiation therapy
was shown to have clear benefits compared to surgery alone by the Mayo Clinic and Medical
College of Virginia which used retrospective and matched-pair analysis. (4,5) Post-operative
radiation therapy was also shown to be superior to pre-operative radiation therapy in terms of
local-regional control for the head and neck. (6) However even with the administration of
post-operative radiation therapy, advanced head and neck carcinomas continued to have
survival rates between 30-40%. (6)
outcomes.

Chemotherapy was added in an effort to improve

The landmark Intergroup 0034 trial looked at postoperative chemotherapy

followed by radiotherapy, compared to post-operative radiotherapy alone, concluding no
survival benefit for those treated with chemotherapy. (14) The chemotherapy was tolerable,
did not restrict the adequate delivery of post-operative radiation, and slightly, but
significantly decreased distant metastasis. (14) Consequently, post-operative chemotherapy
was instituted in treatment regimens of squamous cell carcinoma of the head and neck, but
outcomes continued to remain dismal. (15)
Platinum derived analogs and specifically cis-diamminoplatinum [II] (cisplatin) are
the agents most often delivered concomitantly with radiation in the treatment of locally
advanced squamous cell carcinomas of the head and neck. Cisplatin induces radiation
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sensitization under oxic and hypoxic conditions, enhances formation of toxic platinum
intermediates in the presence of radiation induced free radicals, and a radiation-induced
increase in cellular platinum uptake. (41-45) Platinum derived compounds thus represent
reference agents to combine radiotherapy in head and neck cancer patients since they are
potentially strong radiosensitizers and active chemotherapeutic compounds to treat squamous
cell carcinomas. Also, mucositis is generally not a dose-limiting toxicity for platin drugs,
facilitating their combination with radiation. (46)
Concurrent chemo-radiation with cisplatin in the post-operative setting has been
investigated in three prospective randomized clinical trials providing strong evidence
supporting concurrent chemotherapy for the enhancement of local-regional control.
(18,19,24,15) Other endpoints remain in conflict: The EORTC study and Bauchaud’s study
showed improvement in overall survival and median time to progression, but the RTOG (9501) did not. (18,19,24,25) These differences have been speculated to be the result of
differing patient eligibility criteria resulting in more high-risk patients enrolled in the RTOG
study. The RTOG (95-01) had more patients with two or more dissected lymph nodes and
oropharynx primary sites than EORTC, which previous studies have shown to be high risk
factors in terms of survival, disease progression, and local control. As compared to the
Bachaud study, and the RTOG 95-01 and EORTC trials that used cisplatin, our study utilized
mitomycin-C as the agent for concurrent chemo-radiation. Mitomycin along with Bleomycin
was also used in the study by Smid et al. (23)
Theoretically, one of the causes of failure of radiation therapy to control squamous
cell carcinoma of the head and neck is the existence within the tumors of viable hypoxic cells
of decreased radiosensitivity. (47,48) There is abundant evidence in the literature supporting
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the existence of hypoxic tumor cells that are relatively resistant to radiation.

(49,50)

Mitomycin is a natural-occuring prototype of the quinone bioreductive alkylating agent class.
The drug and its analogs act as a bi-functional akylating agent that forms DNA to DNA and
DNA to protein crosslinks when activated to the alkylating species; under hypoxic
conditions, a greater number of DNA crosslinks occur for a given dose of mitomycin than
occurs in oxygenated cells. (21) In vitro and in vivo studies at Yale’s Therapeutic Radiology
Department laboratories have shown that mitomycin is preferentially cytotoxic for hypoxic
cells compared with well-oxygenated cells. The drug is not a classic radiation sensitizer, but
is rather independently cytotoxic. (51) It was on the basis of these laboratory findings that
the prospective randomized trials described in this report were designed in an effort to
improve outcome in patients with squamous cell carcinoma of the head and neck being
treated with radiation therapy. The rationale for the treatment used was that radiation therapy,
which is most effective against well-oxygenated cells, used in combination with mitomycin,
which is selectively cytotoxic to hypoxic cells, would theoretically result in an enhanced
therapeutic ratio. (52)
Our results demonstrate a statistically significant 15% local-regional control
improvement at both 5 and 10 years, for those receiving combined modality therapy. These
results are also consistent with the study by Smid et al, who demonstrated a 17%
improvement in local-regional control.

Smid also showed a small but significant

improvement in survival using Mitomycin-C. Overall survival and distant metastasis rates
were not significantly improved with the combination in our studies. While all of these
studies using concurrent chemo-radiation in the postoperative setting appear to show similar
15-20% improvements in local-regional control, the survival benefits are clearly conflicting.
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This is likely due to different patient populations, varying co-morbidities and other selection
biases in patient accrual to these studies.
Table 5 presents data re-stratifying our patients according to high-risk factors such as
positive margins, two or more dissected lymph nodes, and oropharynx primary site
comparing outcomes of those patients with such risk factors to the RTOG 95-01 and EORTC
trials. The argument had been made that the EORTC showed an improvement in overall
survival because the EORTC had a smaller percentage of patients with 2 high-risk factors:
oropharynx primary sites and 2 or more lymph nodes, while the RTOG (95-01) had a lower
percentage of patients with positive margins. By the same argument, since the percentage of
our patients with oropharynx primary sites, positive margins, and 2 or more lymph nodes was
even smaller than the EORTC, we should have seen similar improvements in overall survival
to the EORTC. However, our outcomes parallel those of RTOG (95-01), not EORTC, and
provide evidence that eligibility criteria alone cannot justify the difference in overall survival
and other possible confounding variables should be studied.
The aggressive approach of concurrent chemo-radiation does not provide benefits
without a cost. There is a significant increase in acute and late toxicity (grade 3 or higher),
including hematologic, in the RTOG trial, which was not present in the EORTC study.
Mitomycin-c also showed increased grade 3 and 4 toxicities in our study. Although there
were no deaths related to the toxicity, the treatment might need to be reserved for patients
who are only deemed high enough risk to deserve it. There is a growing body of evidence
demonstrating that treatment can be tailored, with more aggressive regimens being more
appropriate for more aggressive tumors and less aggressive regimens being more appropriate
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for less aggressive tumors. The issue of triaging head and neck patients with respect to high
risk factors has been advocated in many recent publications and editorials. (53-55)
Previous studies by the RTOG 8503 and MD Anderson, which were described in the
introduction, have shed some light on the potential high risk factors and their influence on
patient outcomes. The issue is far from clear, however, and further identification is still
considered necessary to accurately triage patients. Recently, the data from EORTC and
RTOG 95-01 has been reanalyzed by pooling the two trials and using a collaborative
comparative analysis of selection criteria, clinical and pathologic risk factors, and treatment
outcomes. Patients who were eligible for both trials, namely ECE and positive margins,
showed statistically significant improvements in local-regional control, disease free survival
and overall survival. (56) Patients who had two or more histopathologically positive lymph
nodes did not appear to benefit from the addition of chemotherapy on any of the endpoints.
A subset analysis of the high risk factors from this report, showed most of our initial
trials had not been constructed with the power to adequately evaluate risk factors
independently. However, we did observe improvements in local-regional control (within
90% confidence) for those patients who had two or more positive lymph nodes and were
treated with mitomycin-c. This potential trend toward local control could provide some
rationale in favor of concurrent chemo-radiation in patients with multiple positive lymph
nodes, which was not observed in the other two trials.
In the future, more trials should be done to assess the benefit of different concurrent
schedules (daily or weekly), alternative cytotoxic agents (e.g., taxane), or drugs designed to
counteract a growth promoting signal (e.g., an anti-epidermal growth factor receptor [EGFR]
drug.) (53) Song and colleagues’ recent review of the role of EGFR targeted therapies in
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combination with radiation therapy for head and neck cancer illustrates the potential appeal
of such approaches. (57) Bonner et.al. recently published a phase III trial in the New
England Journal of Medicine showing that patients with SCCHN who received cetuximab, a
monoclonal antibody against the ligand-binding domain of EGFR, demonstrated an overall
survival benefit without added toxicity. With current improvements in local-regional control
more intensive analysis should be given to controlling distant metastases and more trials
employing induction chemotherapy followed by surgery and adjuvant concurrent chemoradiation might also be examined. Of course, such treatment regimens once again heighten
the potential for severe toxicities and their risk needs to be balanced against therapeutic
gains. Finally, from a radio-therapeutic standpoint, altering fractionation with concurrent
chemo-radiation is still being actively investigated.
In conclusion, mitomycin-C when used concurrently with radiation in post-operative
patients with advanced squamous cell carcinoma of the head and neck, offers significant
improvement in local-regional control. The acceptable toxicity profile, as well as the
significant gains observed justify its consideration as an adjunct to radiation therapy in the
postoperative setting.
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